The future is now: Model-based clinical trial design for Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative* for the Coalition Against Major Diseases**

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume97
Issue number3
DOIs
StatePublished - Mar 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'The future is now: Model-based clinical trial design for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this